Individualised care plans that take greater account of the behavioural and psychological needs of residents are needed
The prescribing of psychotropic medication for people living in residential aged care facilities (RACFs) is of concern to the community, as reflected in evidence presented to the Royal Commission into Aged Care Quality and Safety.1 Although there is a tendency to blame the prescribers, it is increasingly recognised that many RACFs are poorly equipped for managing cognitively impaired older people with challenging behaviours, particularly ambulant residents with dementia. Not all RACFs have adequate circulation space for reducing the likelihood of aggressive incidents, or accessible outside areas for regular physical exercise. Some RACFs have insufficient natural light for maintaining normal sleep/wake cycles, and many do not have enough staff trained in managing the behavioural and psychological symptoms of their residents. In some locations, public sector mental health services can assist with the assessment and management of RACF residents with mental illness or challenging behaviour, but these services are often under‐resourced and unable to respond quickly. In addition, Dementia Support Australia (https://dementia.com.au) offers multidisciplinary assessment and management advice.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Royal Commission into Aged Care Quality and Safety. Restrictive practices. In: Interim report: Neglect, volume 1. Canberra: Commonwealth of Australia, 2019; pp. 193–216. https://agedcare.royalcommission.gov.au/publications/Documents/interim-report/interim-report-volume-1.pdf (viewed Feb 2020).
- 2. Ballard CG, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev 2006; CD003476.
- 3. Harrison SL, Sluggett JK, Lang C, et al. The dispensing of psychotropic medicines to older people before and after they enter residential aged care. Med J Aust 2020; 212: 309–313.
- 4. Banerjee S, Hellier J, Romeo R, et al. Study of the use of antidepressants for depression in dementia: the HTA‐SADD trial: a multicentre randomised, double‐blind, placebo‐controlled trial of the clinical effectiveness and cost‐effectiveness of sertraline and mirtazapine. Health Technol Assess 2013; 17: 1–166.
- 5. Morton R. Outsourcing to hit “dysfunctional” aged‐care system. The Saturday Paper (Melbourne), 2–8 Nov 2019. https://www.thesaturdaypaper.com.au/news/politics/2019/11/02/outsourcing-hit-dysfunctional-aged-care-system/15726132009026 (viewed Mar 2020).
- 6. Ballard C, Margallo LM, Theodoulou M, et al; Investigators DART AD. A randomised, blinded, placebo‐controlled trial in dementia patients continuing to take or stopping neuroleptics (the DART‐AD trial). PLoS Med 2008; 5: e76.
- 7. Devanand DP, Mintzer J, Schultz SK, et al. Relapse risk after discontinuation of risperidone in Alzheimer's disease. N Engl J Med 2012; 367: 1497–1507.
- 8. Patel AN, Lee S, Andrews HF, et al. Prediction of relapse after discontinuation of antipsychotic treatment in Alzheimer's disease: the role of hallucinations. Am J Psychiatry 2017; 174: 362–369.
No relevant disclosures.